Data Insights

Sirexatamab by Leap Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Sirexatamab by Leap Therapeutics for Esophageal Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Esophageal Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Endometrial Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Endometrial Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Gastric Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Gastric Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Colorectal Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Colorectal Cancer